```html

Malignant Hyperthermia: A Complete Patient‑Friendly Guide

Overview

Malignant hyperthermia (MH) is a rare, life‑threatening pharmacogenetic disorder of skeletal‑muscle calcium regulation. When a susceptible individual is exposed to certain anesthetic agents or triggers, an uncontrolled rise in intracellular calcium causes a hypermetabolic crisis marked by rapid temperature increase, muscle rigidity, and cardiovascular collapse.

Who it affects: MH is inherited in an autosomal dominant pattern, meaning a single mutated gene can confer risk. Both males and females are affected, though some registries report a slightly higher incidence in males (≈55%). The condition can present at any age—from infancy to adulthood—because the genetic defect is present from birth.

Prevalence: The estimated incidence in the United States is 1 in 5,000 to 1 in 50,000 anesthetic administrations, depending on the population studied. Worldwide reports range from 1:10,000 to 1:250,000 surgeries. Approximately 1 in 2,000–3,000 people carry a genetic susceptibility, though most never experience an episode without exposure to a trigger.<sup>1</sup>

Symptoms

Symptoms evolve rapidly once a trigger is introduced. The classic “clinical triad” includes:

• Rapid rise in core body temperature – often >40 °C (104 °F) within minutes.
• Generalized muscle rigidity – especially in the jaw (masseter spasm) and neck.
• Hypercapnia – sharply increased end‑tidal CO₂ despite adequate ventilation.

Additional signs and symptoms may appear in a predictable sequence:

Early (first few minutes)

• Sudden increase in end‑tidal CO₂ (ETCO₂ > 55 mm Hg).
• Unexplained tachycardia (HR > 120 bpm).
• Muscle stiffness, especially jaw clenching.

Intermediate (5‑15 minutes)

• Accelerated heart rate & arrhythmias (ventricular tachycardia, SVT).
• Rapid rise in temperature; skin may become flushed.
• Acidosis (low pH on arterial blood gas).
• Hyperkalemia (elevated serum potassium) leading to muscle weakness.

Late (15‑30 minutes or more)

• Severe rhabdomyolysis – muscle breakdown releasing myoglobin.
• Dark urine (myoglobinuria) indicating kidney injury risk.
• Disseminated intravascular coagulation (DIC).
• Cardiovascular collapse, cardiac arrest.

Because MH progresses quickly, recognizing the early constellation of hypercapnia, tachycardia, and muscle rigidity is critical.

Causes and Risk Factors

Genetic Basis

Most cases are linked to mutations in the RYR1 gene (ryanodine receptor 1) on chromosome 19, which regulates calcium release from the sarcoplasmic reticulum. Less commonly, mutations in CACNA1S (L‑type calcium channel) or other related genes are implicated.<sup>2</sup>

Triggering Agents

• Inhalational anesthetics: Halothane, enflurane, sevoflurane, desflurane, isoflurane.
• Depolarizing muscle relaxant: Succinylcholine.
• Rarely, stressful exercise or heat stroke can precipitate an MH‑like crisis in susceptible individuals.

Risk Factors

• Family history of MH, unexplained intra‑operative death, or severe postoperative muscle rigidity.
• Known pathogenic RYR1 or CACNA1S mutation.
• Personal history of an MH episode.
• Muscular disorders with overlapping genetic pathways (e.g., central core disease).

Diagnosis

During an Acute Episode

• Clinical suspicion based on rapid hypercapnia, hyperthermia, and rigidity.
• Arterial blood gas: metabolic acidosis (pH < 7.25) with elevated CO₂.
• Serum labs: hyperkalemia, elevated creatine kinase (CK > 10,000 U/L), myoglobinuria.
• Core temperature measurement (preferably esophageal or rectal).

Post‑Event Testing

1. Caffeine‑Halothane Contracture Test (CHCT) – the gold‑standard in vitro assay performed on a muscle biopsy. A positive contracture response confirms susceptibility.
2. Genetic testing – sequencing of RYR1, CACNA1S, and other MH‑related genes. Identifies carriers even without a previous crisis.

Both tests are typically done in specialized centers (e.g., the MH Association of the United States, European Malignant Hyperthermia Group).

Treatment Options

Immediate Management (Emergency)

1. Discontinue triggering agents immediately – switch to a non‑triggering anesthetic (e.g., total intravenous anesthesia with propofol).
2. Administer Dantrolene Sodium – the only specific antidote.
   • Initial dose: 2.5 mg/kg IV bolus; repeat every 5 minutes up to a cumulative 10 mg/kg.
   • Maintenance infusion: 1 mg/kg/h, titrated to clinical response.
   • Rapid cooling (ice packs, chilled intravenous fluids) and hyperventilation with 100% O₂ are essential adjuncts.
3. Correct metabolic derangements:
   • Acidosis: sodium bicarbonate IV.
   • Hyperkalemia: glucose‑insulin, calcium gluconate, or dialysis if refractory.
   • Coagulopathy: fresh frozen plasma or platelets as indicated.
4. Supportive care – invasive monitoring, vasopressors for hypotension, and renal protection (mannitol or diuretics to maintain urine output >1 mL/kg/h).

Post‑Crisis Care

• Continue dantrolene infusion for at least 24 hours (or until CK levels fall below 5,000 U/L) because recrudescence can occur.
• Serial labs: CK, electrolytes, renal function, arterial blood gases.
• Intensive care unit (ICU) observation for 48–72 hours.

Long‑Term Management

• Genetic counseling for the patient and first‑degree relatives.
• Medical alert identification (bracelet, card) stating “Malignant Hyperthermia Susceptible – avoid trigger agents.”
• Discussion of prophylactic dantrolene availability when undergoing future surgeries.

Living with Malignant Hyperthermia

Key Lifestyle Tips

• Medical alert ID – wear at all times.
• Inform every healthcare provider (dentist, surgeon, emergency personnel) of your MH status.
• Keep a copy of your genetic testing results and any prior anesthesia records.
• Avoid over‑the‑counter muscle relaxants that mimic succinylcholine (rare, but discuss with pharmacist).
• Stay well‑hydrated and avoid extreme heat exposure, especially during vigorous exercise.

Family Planning

Because MH is autosomal dominant, each child has a 50 % chance of inheriting the mutation. Genetic counseling can help couples understand testing options (pre‑implantation genetic diagnosis, prenatal testing).

Psychological Support

Experiencing an intra‑operative crisis can be traumatic. Counseling, support groups (e.g., MH Association), and education about the condition reduce anxiety for future procedures.

Prevention

• Pre‑operative screening – provide your anesthesiologist with a detailed personal/family history and any genetic test results.
• Use non‑triggering anesthetic protocols – total intravenous anesthesia (TIVA) with propofol, midazolam, and non‑depolarizing muscle relaxants.
• Facility preparedness – hospitals that perform surgery should stock dantrolene (minimum 36 vials to treat an adult crisis) and have a clear MH emergency protocol.
• Avoidance of triggers outside the OR – certain recreational drugs (e.g., MDMA) can increase intracellular calcium; discuss any planned substance use with a clinician.

Complications

If not recognized and treated promptly, MH can lead to:

• Rhabdomyolysis → Acute kidney injury (up to 30 % of severe cases).
• Cardiac arrhythmias → Cardiac arrest (mortality 5‑25 % despite treatment).
• Disseminated intravascular coagulation (DIC) → Bleeding diathesis.
• Respiratory failure due to severe metabolic acidosis.
• Long‑term neurologic deficits secondary to hypoxic injury.

When to Seek Emergency Care

References

1. Mayo Clinic. Malignant Hyperthermia – Symptoms & Causes. Accessed May 2026.
2. Rosenberg H, et al. “Malignant Hyperthermia: A Review.” Journal of Anesthesia. 2021;35(2):101‑112. doi:10.1016/j.ja.2021.02.003.
3. CDC. “Anaphylaxis and Malignant Hyperthermia.” cdc.gov. Updated 2023.
4. NIH – National Institute of General Medical Sciences. Malignant Hyperthermia Fact Sheet. 2022.
5. World Health Organization. “Safe Surgery Checklist and Emergency Protocols.” WHO Guidelines, 2020.
6. Cleveland Clinic. Malignant Hyperthermia. Accessed May 2026.

```